Generic-drug manufacturer Actavis agreed to pay approximately $25 billion, or $89.48 per share, to purchase Forest Laboratories in a cash-and-stock deal expected to be finalized by the middle of this year. The acquisition will combine the firms' growing specialty pharmaceutical portfolios and will give Actavis a major focus on higher-margin, brand-name drugs for Alzheimer's disease, high blood pressure and more. "With this strategic combination, we create an innovative new model in specialty pharmaceuticals leadership, with size and scale, a balanced offering of strong brands and generics," Actavis Chairman and CEO Paul Bisaro said.
Forest Laboratories acquired by Actavis for $25B
SmartBrief Job Listings for Health Care
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|Catheter Engineer Manager||
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|
|Neurovascular Intervention Product Sales Rep, North East||
|Multiple Locations, SL_Multiple Locations|
|Senior Manager, Compliance||
|Director, Office of Device Evaluation||
FDA, Center for Devices and Radiological Health
|Silver Spring, MD|